]>
IRCT20220317054318N1 IRCT 2022-05-01 Hamedan University of Medical Sciences The effect of oral L-arginine consumption on uterine artery resistance in women with recurrent implant failure RIF(Frequent implantation (failure The effect of oral L-arginine consumption on uterine artery resistance in women with recurrent implant failure 2022-05-22 anticipated 72 Complete https://irct.ir/trial/62856 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For this purpose, a random block is used. 18 sheets of paper are prepared and the letter A is written on 9 sheets and the letter B is written on the other 9 sheets. The sheets are mixed together and placed in a box and placed in a drawer. And with the reference of each person eligible to enter the study, one of the sheets is randomly taken out and based on whether it is group A or B, it is given to the intervention and control group and the sheets are taken out until every 18 sheets. If it is not pulled out, it will not be returned to the drawer, and after randomly pulling out all 18 sheets, all the sheets will be returned to the drawer and the above operation will be continued up to 4 times on the next 18 patients, ie completing the sample volume to 72, Blinding description: L-arginine and placebo are exactly the same, and a technician who is not in the research plan prepares the drugs and gives them to the doctor, and the codes remain secret until the end of the research, so the patient and the doctor measure the outcome. And the statistical consultant will not know which group these results belong to until the end of the study and after the disclosure of the codes. 3 infertility. Intervention 1: Intervention group: In the intervention group, women with recurrent implant failure, in addition to receiving drugs (including: folic acid, vitamin D3, B complex and probiotics) and standard protocol (LONG with suppression), take Karen brand oral L-arginine supplement from the luteal phase to They receive 3 grams daily for 20 days. Intervention 2: Control group: Women with recurrent implant failure who use standard drugs (including: folic acid, vitamin D3, B complex and probiotics). Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information
public Shamim Pilehvari
Pasdaran street
Hamedan Iran (Islamic Republic of) 6517789971 +98 81 3834 0266 Sh.pilevar@umsha.ac.ir Hamedan University of Medical Sciences scientific Shamim Pilehvari
Pasdaran street
Hamedan Iran (Islamic Republic of) 6517789971 +98 81 3834 0266 Sh.pilevar@umsha.ac.ir Hamedan University of Medical Sciences Iran (Islamic Republic of) Infertile women aged 18-41 years Infertile IVF candidate women with a history of failure twice Women with endometrium suitable for embryo transfer Women with good quality embryos for transfer Women who have passed 2 months or more since the last ICSI test and transfer. Women who have the opportunity to attend the follow-up according to the plan and have informed consent Women with a normal size and shape of the uterus that has been confirmed by ultrasound or hysteroscopy 18 years 41 years Female Patients who use nitrite or organic nitrate at the same time Women with chronic diseases such as: severe liver, kidney, or cardiovascular failure, patients with a history of stroke or myocardial infarction Women smokers Women with stage 3 and 4 endometriosis Women with a known etiology of implant failure such as anatomical disorders (diagnosed by hysterosalpingography), hormonal disorders, immunological disorders, trophoblasts, antiphospholipid antibodies, mutation in factor V, pro-thrombin, crew disorders Musomes are excluded from the study Patients with side effects of L-arginine Canceling the treatment cycle for any reason Unwillingness of the person to continue participating in the study N97.9 Female infertility, unspecified Treatment - Drugs Treatment - Drugs Intervention group: In the intervention group, women with recurrent implant failure, in addition to receiving drugs (including: folic acid, vitamin D3, B complex and probiotics) and standard protocol (LONG with suppression), take Karen brand oral L-arginine supplement from the luteal phase to They receive 3 grams daily for 20 days. Control group: Women with recurrent implant failure who use standard drugs (including: folic acid, vitamin D3, B complex and probiotics) Uterine vascular resistance. Timepoint: At the beginning of the intervention and after taking L-arginine. Method of measurement: Color Doppler ultrasound. Pregnancy. Timepoint: After taking the drug and transferring the fetus. Method of measurement: B-HCG titration test. Hamedan University of Medical Sciences Approved 2022-04-09 Ethics Committee of Hamadan University of Medical Sciences Pasdaran Street Hamedan Hamadan Iran (Islamic Republic of)